Cingulate Stock

$5.17

7.48% yesterday

Nasdaq, Jul 18, 10:19 pm CET

ISIN

US17248W3034

Symbol

CING

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Cingulate Stock price

$5.17

-1,062.83 99.52% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

+0.36 7.48%

ISIN

US17248W3034

Symbol

CING

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$22.0m

Enterprise Value

$17.5m

Net debt

positive

Cash

$9.5m

Shares outstanding

3.8m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

3.7

Financial Health

Equity Ratio

50.2%

Return on Equity

-208.5%

ROCE

-239.5%

ROIC

Debt/Equity

0.9

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-15.8m | -

EBIT

$-16.4m | $-13.2m

Net Income

$-16.4m | $-12.1m

Free Cash Flow

$-14.3m

EPS

$-4.5

FCF per Share

$-3.7

Short interest

5.8%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Cingulate Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Cingulate forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Cingulate forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Cingulate

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	6.54 6.54	2% 2% -
- Research and Development Expense	9.86 9.86	35% 35% -
EBITDA	-16 -16	26% 26% -
- Depreciation and Amortization	0.65 0.65	0% 0% -
EBIT (Operating Income) EBIT	-16 -16	25% 25% -
Net Profit	-16 -16	27% 27% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cingulate Stock News

Neutral

GlobeNewsWire

●

2 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025

Neutral

GlobeNewsWire

●

3 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide

Neutral

GlobeNewsWire

●

4 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.

Head office	United States
CEO	Shane Schaffer
Employees	13
Founded	2013
Website	www.cingulate.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now